UK Markets close in 3 hrs 32 mins

NVO Dec 2021 92.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.57000.0000 (0.00%)
As of 1:40PM EDT. Market open.
Full screen
Previous close1.5700
Open1.3000
Bid1.4500
Ask1.6500
Strike92.50
Expiry date2021-12-17
Day's range1.3000 - 1.5700
Contract rangeN/A
Volume11
Open interest12
  • Reuters

    Novo Nordisk says lower insulin prices in China dent 2022 outlook

    Novo Nordisk on Friday forecast its sales growth would slow by about 3% in 2022 because of lower prices and a drop in insulin sales volumes in China, denting the Danish diabetes drug maker's share price. The forecast comes after Novo received results from China's Volume Based Procurement (VBP) tender, which covers insulin sold at Chinese hospitals. "Novo Nordisk currently expects an estimated negative impact on global sales growth of around 3% in 2022 as a result of reduced prices and reduced volumes of insulin sold in China," it said in a statement.

  • Globe Newswire

    Novo Nordisk announces impact from Volume Based Procurement for insulin in China

    Bagsværd, Denmark, 26 November 2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender for insulin in China. The Chinese National Healthcare Security Administration has tendered insulin sold at hospitals, and Novo Nordisk has participated in the tender. All Novo Nordisk’s insulin were included in the tender except for Ryzodeg® and Xultophy®. Novo Nordisk currently expects an estimated negative impact on global sales growth of a

  • Motley Fool

    4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

    The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.